Prognostic value of lactate dehydrogenase in prostate cancer patients：a Meta-analysis
Yuejun Tian,Xingchen Liu,Yunyun Xu,Ruixia Meng,Weiwei Hu,Jianzhong Lu,Mei Hong,Yuhan Wang,Zhiping Wang
DOI: https://doi.org/10.3969/j.issn.1008-0848.2016.06.004
2016-01-01
Abstract:Objective To systematically review the correlation between lactate dehydrogenase (LDH) and prognosis of prostate cancer (PCa).Methods Using databases including PubMed, EMbase, Chinese CNKI, and WanFang, we collected the published literatures related to the correlation between LDH level and prognotic features of prostate cancer from inception to March 1 st, 2016. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies. Then we used RevMan 5.3 software to perform meta-analysis.Results A total of 17 retrospective cohort studies involving 4390 cases of prostate cancer were included. In the univariate analysis, of the 11 studies investigating the association between LDH level and overall survival (OS), 3 involved Asian patients and 8 involved European-American patients. The overall HR and 95 % CI for PCa patients was 2.93 (95 % CI 2.41~3.56,P < 0.00001). Subgroup analyses showed that the risk was significant in both Asian and European-American patients (Asian: HR = 3.33,95 % CI 2.16~5.16,P < 0.00001;European-America: HR = 2.86, 95 % CI = 2.29~3.57,P < 0.00001). In the multivariate analysis, of the 14 studies investigating the association between LDH level and OS, 7 involved Asian patients and 7 involved European-American patients. The overall HR and 95 % CI for PCa patients was 2.37 (95 % CI 2.12~2.65,P < 0.00001). A subgroup analysis by ethnicity suggested that elevated lactate dehydrogenase level patients showed worse prognosis than low lactate dehydrogenase level patients among both Asian and European-American populations (Asian: HR = 2.50, 95% CI = 1.85~3.38,P < 0.00001; European-America: HR=2.35, 95% CI = 2.08~2.65,P < 0.00001).Conclusion Our meta-analysis results suggest that lactate dehydrogenase may be a prognostic predictor in prostate cancer, which is helpful for rational prognosis prediction and personalized medicine design.